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Conclusions: This subgroup analysis conﬁrms that erlotinib is an ac-
tive and safe therapy when used as third or successive line of treatment 
in patients with advanced or metastatic disease. In the multivariate 
analysis never smoking history is the most signiﬁcant predictive factor 
for longer TTP and OS.
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Background: Erlotinib, an oral HER-1/EGFR TKI is approved for 
patients with locally advanced or metastatic NSCLC after failure of 
at least one prior chemotherapy regimen. Erlotinib showed beneﬁt in 
terms of response rate, time to progression, and overall survival in a 
randomized, placebo-controlled trial. Although exploratory analysis 
demonstrated that the clinical beneﬁt of erlotinib was observed across 
most patient subgroups, this beneﬁt seemed to be greater in certain 
patients groups. Some authors have recommended considering salvage 
chemotherapy in the 2nd line setting instead of erlotinib for those 
patients with a good performance status. The purpose of the analysis 
we present here is to describe clinical outcome in the group of patients 
with NSCLC who presented with good PS (0–1)
Methods: The TargeT trial was an open-label, multicenter, non-ran-
domized phase II clinical trial carried out in 103 Spanish institutions. 
Patients with histologically conﬁrmed stage IIIB or IV NSCLC who 
had received treatment with chemotherapy in second or third line as 
well as chemotherapy-naïve patients non suitable for ﬁrst line conven-
tional chemotherapy were eligible. Eligibility criteria were: ≥18 years 
old, ECOG 0–2, adequate bone marrow, hepatic and renal function and 
written informed consent. Male patients receiving erlotinib 150 mg/day 
p.o until disease progression or withdrawal were the subject of this 
analysis. 
Results: From April 2004 to March 2006, 1,796 patients were included 
in the TargeT trial, of those 1,153 (64%) presented with performance 
status ECOG 0–1 at the beginning of the treatment with erlotinib, be-
ing the subject of this analysis. Main baseline characteristics: median 
age 64 years (range 26-89); 71% were male and 78% active or former 
smokers; histology: 53% adenocarcinoma (including BAC), 26% squa-
mous; 15% large cell carcinoma; 7% other; 82% had metastatic disease. 
Percentage of patients receiving erlotinib in 1st/2nd/3rd or further lines 
was: 27/40/33.
Among 731 patients with evaluable disease, treatment with erlotinib 
yielded an overall response rate (RR) of 19% and 39% of stabiliza-
tion of disease, for an overall control disease rate of 58%. Higher RRs 
were associated with female gender (36%; p<0.0001), non-smoking 
history (41%; p<0.0001), adenocarcinoma histology (26%; p<0.0001) 
and treatment with erlotinib in the ﬁrst line setting (33%; p<0.0001), in 
the univariate analysis. Similar associations were detected in terms of 
disease control ratio (60–70% in all subsets).
In the ITT population, median TTP was 4.1 months [95% CI 3.6–4.5] 
and median overall survival was 7.2 months (95% CI 6.5–7.8). Treat-
ment with erlotinib in chemo-naïve patients and the absence of smok-
ing habits were predictive factors for both a longer TTP and overall 
survival in the multivariate analysis. It deserves a mention that the 
subgroup of patients treated with erlotinib in the ﬁrst line setting (59% 
men; 76% stage IV; 63% non-smokers) reached a median OS of 9.4 
months (95% CI: 7.6–12.0), whilst non-smokers (79% treated in 2nd, 
3rd or further lines) showed a median OS of 13.4 months (95% CI: 
10.0–16.7).
Treatment with erlotinib was well tolerated and non unexpected toxici-
ties were reported. Skin rash and diarrhoea were the most common 
reported toxicities.
Conclusions: Erlotinib is active and well tolerated in patients with 
good performance status. Indirect comparisons suggest meaningful 
beneﬁt of erlotinib in patients with PS ECOG 0–1. On the basis of 
these results, there is no rational to delay the treatment with erlotinib in 
patients with good performance status, therefore potential candidates to 
receive conventional chemotherapy.
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Background: Erlotinib, an EGFR tyrosine kinase inhibitor, is a new 
second-line therapeutic option for patients with NSCLC. Erlotinib has 
been shown to achieve comparable improvement in overall survival, 
but with a more favourable side effect proﬁle than standard chemo-
therapy regimens. Another advantage of this agent is the use of oral 
administration. The favourable tolerability proﬁle of erlotinib may be 
beneﬁcial to the patients’ quality of life, and may lead to cost-savings 
for the health care system. The objective of this study was to evaluate 
the costs of treatment per patient in Germany for erlotinib, docetaxel 
and pemetrexed, taking into account the costs of managing adverse 
events (AEs).
Methods: The treatment regimens considered were continuous 
daily dosing with erlotinib (150mg/day, p.o.), and a 21-day cycle of 
docetaxel (75mg/m2 i.v.) or pemetrexed (500mg/m2 i.v.). Base costs 
and total costs per patient per quarter were calculated for the three 
regimens. The base costs comprised the outpatient costs for medical 
surveillance, drugs and drug administration, disregarding the costs of 
managing AEs. Costs of co-medications (dexamethasone for patients 
treated with docetaxel; dexamethasone, folic acid and vitamin B12 for 
patients treated with pemetrexed) were also considered. Total costs 
included the base costs plus, for each regimen, the average cost per 
patient of treating AEs in outpatient and inpatient facilities (only grade 
3/4 AEs (NCIC-CTC) were considered). Resource utilisation data were 
obtained from two multinational, randomized phase III trials in patients 
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with advanced relapsed NSCLC (Shepherd et al. NEJM 2005;353:123-
32; Hanna et al. J Clin Oncol 2004;22:1589-97). Further required data 
were estimated from national guidelines and prescribing information 
for the drugs considered. The analysis was conducted from the perspec-
tive of German healthcare funding bodies. Cost data were obtained 
from published sources for the year 2005. Costs of medical services 
were derived from EBM 2000plus (the current physicians’ uniform fee 
scale). Drug costs in the outpatient setting were taken from the IfAP® 
Index drug price list. For hospital admissions due to AEs, the disease 
related groups for lung cancer were used. Reﬂecting the social health 
insurance (SHI) system, patient co-payments for drugs and hospital 
treatment, and the legally required discounts from pharmacists and drug 
manufacturers to the SHI system were both taken into account.
Results: The base cost per quarter per patient treated with erlotinib 
was €8,172, versus €8,055 for docetaxel and €15,870 for pemetrexed. 
Including the cost of managing AEs, the total quarterly cost per patient 
on erlotinib was €8,376, versus €9,976 for docetaxel and €16,596 for 
pemetrexed. Sensitivity analyses indicated that the difference in favour 
of erlotinib was a robust ﬁnding, being maintained across a range of 
cost conditions.
Conclusions: A comparison of total medical care costs per patient 
shows an overall cost advantage for erlotinib over docetaxel. This may 
be attributable to the favourable side effect proﬁle of erlotinib, and par-
ticularly the lack of haematological toxicity. The overall cost advantage 
for erlotinib compared with pemetrexed is a consequence of the lower 
drug costs and lower costs of AE management with erlotinib. The use 
of erlotinib for second-line therapy of NSCLC has been now shown 
to have potential health economic beneﬁts for the German healthcare 
system. 
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Background: Molecular alterations along the EGFR pathway have 
been proposed to be the major determinant of clinical outcome in 
response to EGFR tyrosine kinase inhibition in NSCLC pts. However, 
their potential impact on sensitivity to CHT has not been studied in 
detail.
Methods: Advanced NSCLC pts undergoing CHT were screened for 
EGFR gene mutations (by SSCP and sequencing) and/or increased 
copy number (by FISH), EGFR protein expression (by IHC), and HER-
2, phosphorylated AKT (pAKT), and total AKT protein expression (by 
IHC). Correlation between speciﬁc molecular alterations and clinical 
outcome (ORR, PFS, and OS) was then retrospectively explored using 
both the Cox regression model as well as classiﬁcation and regression 
trees (CART) analysis.
Results: One hundred and twenty seven pts were screened and 93 
received 1st-line CHT. The frequency of EGFR pathway alterations is 
shown in Table 1. At a median follow up of 13 mos, survival analysis 
revealed that true EGFR gene ampliﬁcation is the only signiﬁcant 
predictor of worst OS (p=0.004). No signiﬁcant correlation was 
found with PFS. ORR was signiﬁcantly worse in HER-2-positive pts 
(p=0.03). CART analysis conﬁrmed that true EGFR gene ampliﬁcation 
negatively affect OS, followed by EGFR gene mutation and chromo-
some 7 polysomy in non-ampliﬁed and non-ampliﬁed/non-mutated pts, 
respectively.
Present Absent n.e.
EGFR mutations 7 42 44
EGFR gene ampliﬁcation 10 66 17
#7 Polysomy (≥ 40%) 40 29 24
pAKT (score ≥1+) 56 15 22
EGFR (score ≥1+) 63 15 15
HER-2 (score ≥1+) 36 29 21
Conclusions: EGFR pathway alterations signiﬁcantly impact on 
outcome following 1st-line CHT for advanced NSCLC. HER-2 over-
expression negatively impacts on ORR, but not on PFS and OS. This 
information maybe useful in selecting appropriate treatment algorithm 
for advanced NSCLC pts.
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Background: Erlotinib (Tarceva®), an orally active, potent, selec-
tive inhibitor of HER1/EGFR tyrosine kinase, signiﬁcantly prolonged 
survival, delayed symptom progression, and improved quality of life 
of NSCLC patients (pts) in the BR.21 phase III placebo controlled 
trial. The multicenter, open label EAP was initiated for patients with 
advanced or metastatic NSCLC to provide erlotinib access.
Methods: Stage III/IV NSCLC pts who had failed prior chemotherapy 
or were unsuitable for chemotherapy. Eligible patients were given oral 
erlotinib (150mg/day) until disease progression or unacceptable toxic-
ity. The NCI CTC v3.o was used to evaluate toxicities. Dose reductions 
were allowed. Pts were monitored monthly.
Results: A total of 303 evaluable pts were enrolled in 15 centers, in 12 
months. The analysis was done on 194 pts, who represent 64% of the 
303 pts enrolled in TRUST in Israel. Patient characteristics: median 
age 67 years (range 37-86); male 62%, female 38%; caucasian 97%, 
black 0%, other 1%, no data 2%; ECOG PS0 13%, PS1 42%, PS2 
28%, PS3 16%, no data 1%; Stage IIIB 10%, Stage IV 88%, no data 
2%; Adenocarcinoma 45%, BAC 7%, LCC 6%, SCC 15%, Other 28%; 
Prior chemotherapy: 1st line 23%, 2nd line 45%, 3rd line 28%, other 
4%; Non-smoker 28%, Former or Current-smoker 72%, no data 1%. As 
expected, rash was a common AE mainly mild or moderate:G1 and/or 
2- 49%, G3 and/or 4 9%. Other G3-4 SAE included: diarrhea <1%; 
fatigue 3%; dehydration 1%; urticaria 1%; dyspnea 2%. 17% of pts 
required dose reduction. Dose reductions to 100mg occurred in 14%, 
